University of Salamanca

Belantamab Mafodotin Triplet Demonstrates Improved Overall Survival in Relapsed/Refractory Multiple Myeloma

6 months ago

• The DREAMM-7 phase 3 trial showed that belantamab mafodotin, bortezomib, and dexamethasone (BVd) significantly improved overall survival in relapsed/refractory multiple myeloma patients. • BVd demonstrated a 42% reduction in the risk of death compared to daratumumab, bortezomib, and dexamethasone (DVd), with a projected median OS of 84 months versus 51 months. • The belantamab mafodotin combination also achieved statistically significant superiority in minimal residual disease (MRD) negativity compared to the daratumumab combination. • Regulatory filings for belantamab mafodotin combinations have been accepted in multiple major markets, potentially establishing a new standard of care.

GSK's Blenrep Demonstrates Significant Survival Benefit in Multiple Myeloma Trial, Paving Way for Potential Comeback

6 months ago

• GSK's Blenrep, combined with chemotherapy and a steroid, reduced the risk of death by 42% compared to a standard-of-care treatment in relapsed or refractory multiple myeloma. • The DREAMM-7 trial data showed a projected median overall survival of 84 months for the Blenrep combination versus 51 months for the comparator arm. • Blenrep, an antibody-drug conjugate targeting BCMA, is under regulatory review in multiple regions, potentially offering a new treatment option for myeloma patients. • Despite previous market withdrawal due to a failed trial, Blenrep's new data suggests a possible paradigm shift in treating relapsed or refractory multiple myeloma.

Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) Regimen Shows Significant Benefit in Relapsed/Refractory Multiple Myeloma

a year ago

• The DREAMM-7 study demonstrated that belantamab mafodotin, bortezomib, and dexamethasone (BVd) significantly improved progression-free survival in relapsed/refractory multiple myeloma patients compared to daratumumab, bortezomib, and dexamethasone (DVd). • Median progression-free survival was 36.6 months in the BVd arm versus 13.4 months in the DVd arm (HR = 0.41; P < .0001), with consistent benefits across subgroups, including lenalidomide-refractory and high-risk cytogenetic myeloma. • An early, strong trend toward better overall survival was observed with BVd (HR = 0.57; P = .00049), alongside a doubling in response rates and undetectable measurable residual disease. • While ocular adverse effects were more frequent with BVd, they were generally manageable and reversible, suggesting BVd as a potential new standard of care in second-line or later relapsed/refractory multiple myeloma.